Fm1 Member
  • Member since Mar 28th 2016
  • Last Activity:

Posts by Fm1

    They kill jobs, overwhelm treasuries, harm mental health but COVID lockdowns work, science suggests

    Still, for many lay people and some doctors and scientists , the question has become: Was it all worth it?


    https://nationalpost.com/news/…e6-aca7-296245aca0dd/amp/


    Dr. Ari Joffe is accustomed to being at odds with his scientific colleagues.


    The University of Alberta critical care physician doubts brain death really is death and questions the practice of harvesting donor organs from people shortly after their hearts have stopped beating.

    He did it again last month, publishing a paper that argues the lockdowns used to curb the spread of COVID-19 stem from “group-think” and have done more harm than good.

    “We must open up society to save many more lives than we can by attempting to avoid every case (or even most cases) of COVID-19,” Joffe urged in the journal Frontiers of Public Health.


    Worn out by a year of life in suspension, many Canadians would likely share his sentiments.


    In the battle against the coronavirus, lockdowns have been bitter medicine, causing unemployment not seen since the Great Depression, wiping out myriad businesses, costing government billions and triggering countless mental and physical health side effects.

    Is there some evidence lockdowns work they are basing this decision on? I read articles every day saying at best the evidence is inconclusive.

    Lockdown fatigue: The declining effectiveness of lockdowns


    https://voxeu.org/article/declining-effectiveness-lockdowns


    Conclusions

    These results suggest that restrictions applied for a long period or reintroduced late in the pandemic (for example, in the event of a resurgence of cases) would exert, at best, a weaker, attenuated effect on the circulation of the virus and the number of casualties. Combined with the results in Haug et al. (2020), they suggest that lockdowns should be strict and brief.


    These findings are particularly relevant for emerging and developing countries that may face considerable delays in the start of massive vaccination campaigns and will likely face successive waves of infections without having achieved herd immunity levels. After a year of strong economic downturn and substantial health costs, the intensity of lockdowns continues to be an influential factor in the economic and social life of low- and middle-income countries. Even if restrictions played a role early on, they had a one-off effect that would be hard to replicate going forward. This suggests that the heavy reliance on lockdowns as in the early stages of the pandemic may not be advised.

    COVID-19 is much deadlier in Brazil than India and no one knows why


    https://www.chicagotribune.com…story.html?outputType=amp


    Facing a sudden surge in coronavirus infections, India is once again home to the world’s second-largest outbreak, overtaking Brazil after the latter moved ahead in March. But behind the bleak statistical jockeying is an epidemiological enigma over why the Latin American country has been far more devastated by the pathogen.


    When it comes to the scale of infections, the two nations are similarly matched, with cases hovering near 14 million and hospitals from Mumbai to Sao Paulo under increasing pressure as admissions continue to rise. But it’s the divergence in fatalities that has scientists puzzled. Brazil, home to almost 214 million, has seen more than 361,800 people die from COVID-19, more than double the number of deaths in India, which has a far greater population of 1.4 billion.


    While deaths in India have started climbing and threaten to get worse, the macro-level disparity remains and is emblematic of different ways in which the pandemic is playing out across regions. Experts say this needs to be better understood and decoded, to contain this global outbreak as well as avoid future public health crises.


    COVID-19 death ratios in South Asia, including India, are consistently lower than global averages, just as those in Latin America are consistently higher, forcing virologists to offer a number of theories as to why Covid has cut a more deadly swathe from Brazil to Argentina.


    “We’re not comparing apples to apples here, we’re comparing apples to oranges,” said Bhramar Mukherjee, the biostatistics chair at University of Michigan’s School of Public Health. For now, both countries present an “intriguing puzzle — an epidemiological mystery that needs a Sherlock Holmes or Miss Marple in action.”


    Brazil has been hit by multiple waves killing an alarming number of its young and it reported a record one-day jump of 4,000 COVID-19-related deaths last week. Meanwhile, India’s daily surge in casualties have been around 1,000 and well below that last week. Deaths in the Asian country as a percentage of confirmed cases is 1.2 versus 2.6 in Brazil, data compiled by Bloomberg show.


    Multiple factors could be at play in the fatality gap, including the differences in mean age — 26 years in India to Brazil’s 33.5.


    Experts have long criticized India’s broader death statistics, particularly in its rural hinterlands. Before the pandemic about one in five fatalities were not reported at all, according to Mukherjee. But that doesn’t explain why Brazil’s death rate is higher than aging Western nations that have also been hard hit by the pandemic.


    “Brazil’s mortality rate is even more shocking because the population is much younger than other countries, such as European ones,” said Alberto Chebabo, the vice-president of the Brazilian Society of Infectious Diseases.


    The rising infection and death rates come as the pace of the inoculation drives in each country has sped up in the past month after an initially sluggish start. India has managed to administer more than 114 million vaccine doses, compared to Brazil’s 32 million — though the latter has injected a higher proportion of its population.


    Other theories behind the divergence between Brazil and India center around the two countries’ differing environments and experience of disease.


    Some scientists say widespread exposure to an array of diseases in India may have helped its citizens build natural resilience against coronaviruses such as COVID-19.


    Shekhar Mande, the head of India’s Council of Scientific and Industrial Research, is among those who have examined this trend and co-authored a published study on this. His research found correlations where citizens from low-hygiene nations tended to better cope with COVID-19.


    “Our hypothesis, and this is strictly a hypothesis, is that because our populations are continuously exposed to many kinds of pathogens, including viruses, our immune system does not hyper-react to any new variation that comes in,” Mande said in an interview.


    Many experts acknowledge genetics or cross-immunity could be at play as other South Asian countries including Bangladesh and Pakistan have also seen far fewer deaths than Brazil.


    That 87% of Brazilians live in urban areas, but two-thirds of Indians live in rural places with more space and ventilation could be another reason, according to University of Michigan’s Mukherjee.


    Then there’s the fact that Brazil is where one of the most potentially deadly coronavirus mutations, the P.1 variant, was identified in December. Along with variants first seen in South Africa and the U.K., studies suggest these strains are more contagious.


    “The P.1 variant has spread through a lot of Brazil’s cities and states simultaneously, leading to a collapse of the health system, which has lead to a very high mortality rate,” said Chebabo from the Brazilian Society of Infectious Diseases. Brazil is in a “perfect storm,” he added, with its lack of political leadership in implementing effective measures like lockdowns, compounding the COVID-19 crisis.


    The rapid and sustained spread of the variant in Brazil also gave its health-care system no breathing room, unlike a lull between waves over the last months of 2020 in India, which helped hospitals and frontline workers recover and plan ahead.


    “We’re far better prepared for handling this wave than we were earlier in many, many ways,” Suneeta Reddy, managing director of Apollo Hospitals Enterprises Ltd., said in an interview. “We’ve learned the clinical protocols to treat COVID. We’re able to use our assets and beds in a much more rigorous manner.”


    India could now be facing the prospect of a mutant strain-driven surge that’s worse than its first outbreak, though it’s hard to tell given the Asian nation had done genome sequencing for less than 1% of its COVID-19-positive samples.


    Mismanagement and COVID-19 fatigue have also been blamed for the rampant spread and soaring death rates in both countries. Brazilian President Jair Bolsonaro has long-opposed lockdowns, clashing with local governments over pandemic mitigation measures and ridiculing mask wearing.


    For India, a months-long decline in daily infections from the first peak in September — along with officials lifting restrictions on public gatherings — encouraged people to lower their guard. Many also became indifferent to the dangers of COVID-19 after seeing friends and family with mild symptoms recover and politicians disregard safety protocols.


    “Brazil is a complete disaster in terms of the political leadership, and India has become complacent after the initial decline in cases,” said Madhukar Pai, the Canada research chair in epidemiology and global health at McGill University in Montreal.


    It’s too early to say if India can continue to avoid the more lethal fate of Brazil. While some parts of the country have imposed targeted lockdowns, elections are being held in five states — seeing thousands of voters pack campaign rallies — along with a month-long Hindu pilgrimage that brings throngs to the banks of Ganges river.


    These threaten to undo the benefits that can come from the ramped up vaccination drive. Daily deaths in the South Asian country have already more than doubled to over 1,000 a day in the past week, with crematoriums in many areas running non-stop and bodies piling up.


    “Both countries need to greatly increase their vaccination coverage and work harder to implement other public health measures,” said Pai. “What matters is each country needs to work much harder to contain the epidemic.


    The reason..... Covid is seasonal!!!!!

    Number of COVID-19 patients in French intensive care falls again


    https://www.reuters.com/busine…ntensive-care-2021-04-17/


    The number of coronavirus patients in intensive care units in France has fallen and the number of patients in hospital has also dropped, the health ministry said on Saturday, in a sign that pressure on the medical system is easing.


    Health ministry data showed that 5,877 people were in intensive care units with COVID-19 on Saturday, 37 fewer than on Friday. The number of COVID-19 patients in hospital fell by 143 to 30,329, the fifth consecutive fall.


    France imposed a third nationwide lockdown this month to try to stem its third wave of infections.


    It registered 189 new daily coronavirus deaths in hospitals in the space of 24 hours. Overall, France's COVID-19 death toll breached the 100,000 mark on Thursday, the eighth-highest in the world.

    the EU doesn't have a clue!!


    : 'Highly probable' that the EU won't renew its AstraZeneca contract, says French minister


    https://www.euronews.com/2021/…contract-says-french-mini


    The likelihood that the European Union will renew its COVID vaccine contract with AstraZeneca is very low, according to France's industry minister.


    Agnes Pannier-Runacher told BFM-TV on Friday that final decisions were yet to be made, but that she believed it "highly probable" the bloc would not place any more orders.


    The European Medicines Agency (EMA) has repeatedly said the benefits of the UK-developed vaccine far outweigh any risks - in reference to the potential link found to rare blood clots - however, individual countries have been seen to follow their own course.


    On Thursday, Denmark was the first country to completely abandon the AstraZeneca jab, while Norway later followed suit.


    Countries such as Germany, Belgium, the Netherlands and Spain have restricted use to specific age groups, but none have gone as far to write it off completely

    Agreed. (I was just being my sometimes sarcastic self when I said the study can't be right.)

    If I was personally concerned about getting Covid-19 I would indeed be getting an N95 or higher (N98, N99, etc) mask. The downside with going higher than N95 is that it gets more difficult to breathe, so I've heard. As it is I just use a surgical mask when I go in stores and take the thing off as soon as I leave. The Ivermectin I got some months ago I still have, but is more for any close friend or relative I might hear is having trouble.


    Update: The Premier of Ontario just a few hours ago has lifted the ban on children playgrounds (that had been in place for less than a day)! This came after an uproar from citizens, whose children can't go to school for weeks.

    Canadian police refuse provincial order to make random stops amid COVID-19 surge


    https://www.reuters.com/world/…ovid-19-surge-2021-04-17/


    Police in cities across Ontario, Canada’s most populous province, on Saturday refused to make random stops greenlighted by the provincial government seeking to impose a stay-at-home order amid a surge in COVID-19 cases.


    Toronto, the country’s largest city, Ottawa, Hamilton, Windsor and at least 19 other municipal police forces said they would not conduct random vehicle or individual stops though they had been given the power to do so.


    "The Toronto Police Service will continue to engage, educate and enforce, but we will not be doing random stops of people or cars," the force said on Twitter. Mayor John Tory supported the move.


    Ontario, home to 38% of Canada's population, had 4,362 new infections on Saturday after a record of 4,812 cases on Friday, and projections indicate the virus could spike to 10,000 per day in June without more strict health restrictions.

    Look, here's what I'm saying: I don't want politics mixed in with my medical decisions! And now that everything is politics, that's all we do! If their side says 'COVID is nothing,' our side has to say it's everything. Trump said it would 'go away like a miracle,' and we said it was World War Z," Maher complained. "And now, of course, we find out that all that paranoia bout surfaces was bulls--- anyway... If you lie to people, even for a very good cause, you lose their trust."


    Maher praises DeSantis, knocks Cuomo, 'liberal media' for getting COVID wrong: 'Those are just facts'

    The HBO star slammed 'blue states' for keeping schools closed despite minimal health risks to children


    https://www.foxnews.com/entert…r-getting-covid-wrong.amp


    Real Time" host Bill Maher had some tough words for liberals over their handling of the coronavirus outbreak.


    In his closing monologue Friday night, Maher took aim at the media's "panic porn" during the pandemic, citing a Dartmouth study showing that "nearly 90 percent" of U.S. national media coverage was negative in comparison to other countries even as conditions were getting better.


    Maher also called out politicians who "lie" to "save their own asses."

    When all of our sources for medical information have an agenda to spin us, yeah, you wind up with a badly misinformed population, including on the left," Maher told viewers. "Liberals often mock the Republican misinformation bubble ... but what about liberals? You know, the high-information, behind-the-science people?"


    "Liberals often mock the Republican misinformation bubble ... but what about liberals? You know, the high-information, behind-the-science people?"


    — Bill Mahe


    Maher then pointed to a Gallup survey that showed the vast majority of Democrats incorrectly overestimate the probability of being hospitalized from COVID, with 41 percent believing it's at least 50 percent while only 10 percent of Democrats correctly said that the probability is only 1-to-5 percent while 26 percent of Republicans said the same, stressing that Democrats were "wildly off on this key question."

    Democrats] also have a greatly exaggerated view of the danger of COVID to and the mortality rate among children, all of which explains why today the states with the highest share of schools that are still closed are all blue states," Maher lamented. "So if the right-wing media bubble has to own things like climate change denial, shouldn't liberal media have to answer for 'How did your audience wind up believing such bunch of crap about COVID?'"


    The HBO star blasted The Atlantic magazine for shaming the media's use of beach photos as a concern of furthering the spread of the virus "even though it's increasingly looking like the beach is the best place to avoid it."

    Sunshine is the best disinfectant and Vitamin D is the key to a robust immune system," Maher exclaimed. "Texas lifted its COVID restrictions recently and their infection rates went down in part because of people getting outside to let the sun and wind do their thing. But to many liberals, 'That can't be right because Texas and beach-loving Florida have Republican governors,' but life is complicated!"

    Maher then praised Republican Florida Gov. Ron DeSantis for being "a voracious consumer of the scientific literature."


    "And maybe that's why he protected his most vulnerable population, the elderly, way better than did the governor of New York," Maher said, knocking Democratic Gov. Andrew Cuomo. "Those are just facts, I know it's irresponsible of me to say them."

    Florida Gov. DeSantis "protected his most vulnerable population, the elderly, way better than did the governor of New York."


    — Bill Maher


    Look, here's what I'm saying: I don't want politics mixed in with my medical decisions! And now that everything is politics, that's all we do! If their side says 'COVID is nothing,' our side has to say it's everything. Trump said it would 'go away like a miracle,' and we said it was World War Z," Maher complained. "And now, of course, we find out that all that paranoia bout surfaces was bulls--- anyway... If you lie to people, even for a very good cause, you lose their trust."

    "I think a lot of people died because of Trump's incompetence and I think a lot of people died because talking about obesity became a third rail in America... it is the key piece of the puzzle, by far the most pertinent factor, but you dare not speak its name.Imagine how many lives could have been saved if there had been a national campaign ala Michelle Obama's 'Let's Move' program with the urgency of the pandemic behind it," Maher continued. "If the media and the doctors made the point to keep saying, 'But there's something you can do,' but we'll never know because they never did because the last thing you want to do is say something insensitive. We would literally rather die. Instead, we were told to lock down. Unfortunately, the killer was already inside the house. And her name is Little Debbie."

    United States cases rising, British drop in cases have leveled and Europe is a freaking mess and india is screwed! Question... Do these vaccines work at all? Follow the evidence!


    Chile leads the Western Hemisphere in vaccinations. The coronavirus is still surging.


    https://www.washingtonpost.com…c-vaccine/?outputType=amp


    Chile might have celebrated too soon.


    This South American nation of 19 million, which secured enough potential coronavirus vaccine doses to inoculate its population twice over, leads the Western Hemisphere in vaccinations per capita. More than 7.5 million Chileans have received at least one dose, and 5 million are now fully vaccinated. Only Israel and Britain have performed better.


    At the same time, new cases of covid-19 are surging. The country has reported more than 7,000 daily cases nine times this month, outstripping its first-wave peak of 6,938 last July, and sounding an alarm for the United States and other countries that have raced out ahead on the vaccination curve.

    FDA rescinds emergency authorization for COVID-19 antibody treatment bamlanivimab


    https://thehill.com/policy/hea…19-antibody-treatment?amp


    The Food and Drug Administration (FDA) rescinded its emergency use authorization for the monoclonal antibody bamlanivimab to be used on its own as treatment against COVID-19 due to variants' resistance to the therapy.


    The federal agency declared its cancelation of bamlanivimab-only COVID-19 therapy hours after the company Eli Lilly requested the FDA revoke the emergency authorization because the variants resistant to the treatment have become more common.


    With the number of resistant infections growing, the agency concluded that the benefits of treating COVID-19 with only bamlanivimab "no longer outweigh the known and potential risks for its authorized use."


    The FDA cited data that as of mid-March about 20 percent of variants in the U.S. were expected to be resistant to bamlanivimab, compared to 5 percent in January.

    But the FDA still grants bamlanivimab and another monoclonal antibody, etesevimab, to be used together to treat COVID-19 under an emergency use authorization. In a March study, Eli Lilly determined the combination of monoclonal antibodies - lab-created proteins that copy how the immune system responds to viruses - reduced the risk of hospitalization and death from COVID-19 by 87 percent.


    "Other monoclonal antibody therapies authorized for emergency use remain appropriate treatment choices when used in accordance with the authorized labeling and can help keep high risk patients with COVID-19 out of the hospital," Patrizia Cavazzoni, the director of the FDA's Center for Drug Evaluation and Research, said in a release.


    "We urge the American public to seek out these therapies when needed while we continue to use the best data available to provide patients with safe and effective treatments during this pandemic," Cavazzoni added.

    The emergency use authorization for bamlanivimab-only COVID-19 treatment, granted in November, was the first monoclonal antibody approved to treat mild to moderate COVID-19 cases. It originally allowed it to be used alone for mild-to-moderate COVID-19 adult patients and some children at high risk of severe coronavirus illness or hospitalization.


    The federal agency said it will work with the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) to monitor how variants impact the treatments authorized for emergency use.


    Eli Lilly called for the FDA to end emergency authorization for bamlanivimab-only COVID-19 treatment "due the evolving variant landscape in the U.S. and the full availability of bamlanivimab and etesevimab together." The company noted its request for authorization to be revoked was "not due to any new safety concern."

    Mississippi man partially paralyzed, unable to talk after J&J vaccine


    https://nypost.com/2021/04/15/…alk-after-jj-vaccine/amp/



    NEWS

    Mississippi man partially paralyzed, unable to talk after J&J vaccine

    By Jackie Salo


    April 15, 2021 | 5:20pm



    A Mississippi man who experienced a blood clot after receiving the Johnson & Johnson COVID-19 vaccine, has been left paralyzed on one side and unable to talk, his family said.


    Brad Malagarie, 43, of St. Martin, suffered a stroke soon after stepping out last week to get the one-dose shot, news station WLOX reported.


    “They called me and said he had that vaccine and something is wrong, we think it’s a stroke,” his aunt, Celeste Foster O’Keefe, told the outlet.


    The father of seven was rushed to the hospital, where it was determined that he had a stroke as a result of a blood clot in his brain, the outlet reported.


    “I said be sure to tell the doctors he took that J&J vaccine and that, to me, is what caused his stroke,” his aunt said.

    O’Keefe said he took medication for high blood pressure, but was otherwise a “young, healthy” man.

    Now, the medical episode has left him paralyzed on the right side of his body, she said.


    “He can’t talk now and he can’t walk. He’s paralyzed on the right side. He knows who we are and he will just cry when he sees us,” O’Keefe said.


    She said doctors don’t know how long it will take him to recover.


    “We want him to be able to communicate, to be able to walk and talk again, even if it’s not perfect,” O’Keefe said.


    Federal regulators paused the use of the one-dose J&J shot on Tuesday after six women between the ages of 18 and 48 developed blood clots, including one who died.

    worried about faulty Covid tests? Get a dog!!!


    Discrimination of SARS-CoV-2 infected patient samples by detection dogs: A proof of concept study


    https://journals.plos.org/plos…1371/journal.pone.0250158


    Abstract

    While the world awaits a widely available COVID-19 vaccine, availability of testing is limited in many regions and can be further compounded by shortages of reagents, prolonged processing time and delayed results. One approach to rapid testing is to leverage the volatile organic compound (VOC) signature of SARS-CoV-2 infection. Detection dogs, a biological sensor of VOCs, were utilized to investigate whether SARS-CoV-2 positive urine and saliva patient samples had a unique odor signature. The virus was inactivated in all training samples with either detergent or heat treatment. Using detergent-inactivated urine samples, dogs were initially trained to find samples collected from hospitalized patients confirmed with SARS-CoV-2 infection, while ignoring samples collected from controls. Dogs were then tested on their ability to spontaneously recognize heat-treated urine samples as well as heat-treated saliva from hospitalized SARS-CoV-2 positive patients. Dogs successfully discriminated between infected and uninfected urine samples, regardless of the inactivation protocol, as well as heat-treated saliva samples. Generalization to novel samples was limited, particularly after intensive training with a restricted sample set. A unique odor associated with SARS-CoV-2 infection present in human urine as well as saliva, provides impetus for the development of odor-based screening, either by electronic, chemical, or biological sensing methods. The use of dogs for screening in an operational setting will require training with a large number of novel SARS-CoV-2 positive and confirmed negative samples.

    It seems that some vaccines ARE killing people!!


    People with rare blood clots after a COVID-19 jab share an uncommon immune response


    https://www.sciencenews.org/ar…eneca-johnson-johnson/amp


    Evidence is building that an uncommon immune response is behind dangerous, but incredibly rare, blood clots associated with some COVID-19 vaccines. But the good news is that there is a test doctors can use to identify it and get patients the right care.


    A small number of people out of the millions vaccinated with AstraZeneca’s or Johnson & Johnson’s COVID-19 shots have developed severe blood clots, such as ones in the sinuses that drain blood from the brain (SN: 4/7/21; 4/13/21). A few have died.


    Studies suggest that some inoculated people develop an immune response that attacks a protein called platelet factor 4 or PF4, which makes platelets form clots. Those platelets get used up before the body can make more. So these patients wind up with both the rare clots and low levels of blood platelets.

    Of 23 patients who received AstraZeneca’s jab and had symptoms of clots or low platelets, 21 tested positive for antibodies to PF4, researchers report April 16 in the New England Journal of Medicine. Of those, 20 people developed blood clots. The finding adds to previous studies that found the same antibodies in additional patients who got AstraZeneca’s shot and had the dangerous clots.


    Five out of six women who had clots after receiving Johnson & Johnson’s shot in the United States also had PF4 antibodies, health officials said April 14 during an Advisory Committee on Immunization Practices meeting. That advisory group to the U.S. Centers for Disease Control and Prevention is assessing what needs to be done to lift a temporary pause on administering the Johnson & Johnson jab that was prompted by blood clot concerns (SN: 4/13/21). One man had developed brain sinus clots during the shot’s clinical trial and a seventh case is under investigation, the pharmaceutical company said during the meeting.


    “Because we are aware of this syndrome… we know how to treat it,” says Jean Connors, a clinical hematologist at Harvard Medical School and Brigham and Women’s Hospital in Boston who was not involved in the studies. And unlike the people who developed the clots before officials pinpointed the link, “we can diagnose it faster and treat it more appropriately if it does happen, so that the outcomes will be better.”

    Researchers Detail More Cases of Rare Clots Tied to COVID Vaccines


    https://www.medscape.com/viewarticle/949473


    New evidence emerged today tying vaccines for COVID-19 to extremely rare cases of people who develop blood clots and low platelets within weeks of being vaccinated.


    A team of researchers in the United Kingdom conducted an in-depth investigation of 22 patients who developed serious blood clots combined with a drop in blood platelets after receiving a dose of the AstraZeneca vaccine, which is now called Vaxzevria. They also tested an additional patient who had clinical signs of a drop in blood platelets after vaccination. Nearly all the patients — 22 of 23 — tested positive for unusual antibodies to platelet factor 4, a signaling protein that helps the body coordinate blood clotting.


    The presence of the antibodies suggests that the vaccines are somehow triggering an autoimmune attack that causes large clots to form that then diminish the supply of platelets in the blood.


    The study and an editorial on the cases are published in the New England Journal of Medicine.


    This is at least the third study detailing the presence of these antibodies in patients with blood clots and low platelets after vaccination, and doctors say the emerging evidence suggests that doctors should remain vigilant for this new syndrome in anyone who experiences symptoms of blood clots anywhere in the body, not just the brain.


    James Zehnder, MD, director of the coagulation laboratory at Stanford University School of Medicine in California, said that the mounting evidence pointing to a "maladaptive immune response" was quite remarkable. He was not involved in the research.


    Zehnder says that why this syndrome, which seems to be some kind of an autoimmune attack on a blood signaling protein, develops in a small number of people after they get the anticoagulant heparin or a vaccine for COVID-19 is still very much a mystery.

    He says that while the catastrophic cases of large clots in areas of the brain where doctors don't usually see them stand out, he wonders whether other, less obvious cases are going undetected.


    "Then the question is, you know, how much more of this is going on in a more subtle way? And so I think the true magnitude of it is not known," he says, noting that it will be important in the coming weeks and months to figure out if particular groups of people are at higher risk than others, like young women. "There are many more questions than answers now," he says.


    Key Symptoms to Watch

    The symptoms to watch for include shortness of breath, headaches, dizziness, muscle weakness, or abdominal pain, back pain, or nausea and vomiting in anyone who is within 3 weeks of their vaccinations, including men.


    People who have not been vaccinated can also develop these types of clots, called cerebral venous sinus thrombosis. These cases — whether they happen after a vaccine or not — are extremely rare. On average each year, there are two to 14 cases of these clots in vessels that drain blood from the brain for every million people, according to Peter Marks, from the US Food and Drug Administration.


    Doctors say that, on the whole, all the vaccines authorized to protect people from the new coronavirus are extremely safe. In fact, the risk of developing a life-threatening blood clot is far higher with COVID than with a vaccine.


    "The chances of this happening to you are about between 1 and 100,000 to 1 in 1 million," said John Wherry, PhD, director of the Institute for Immunology at the University of Pennsylvania in Philadelphia. "If you're an American, the chances of dying from COVID are 1 in 600," Wherry continued, citing statistics on US COVID cases and deaths maintained by Johns Hopkins University.

    Doctors home in on cause of blood clots potentially linked with Covid-19 vaccines


    https://amp.cnn.com/cnn/2021/0…possible-cause/index.html


    (CNN)Doctors say they are homing in on the cause of blood clots that may be linked with certain coronavirus vaccines, and said their findings have important implications for how to treat the condition, regardless of whether vaccines cause it.


    Even though the link is not firm yet, they're calling the condition vaccine-induced immune thrombotic thrombocytopenia or VITT. It's characterized by unusual blood clotting combined with a low number of blood-clotting cells called platelets. Patients suffer from dangerous clots and, sometimes, hemorrhaging at the same time.


    It's been linked most firmly with the AstraZeneca coronavirus vaccine, which is in wide use in Europe and the UK.

    The US Centers for Disease Control and Prevention and the Food and Drug Administration are checking to see if Johnson & Johnson's Janssen vaccine also might cause the blood clots. Both AstraZeneca's vaccine and the J&J vaccine use common cold viruses called adenoviruses as a carrier and some experts suspect the body's response to those viral vectors might underlie the reaction. AstraZeneca's vaccine is not authorized in the US.

    The FDA and CDC have asked for a pause in giving out the J&J vaccine while they investigate.


    A team led by Dr. Marie Scully, a hematologist at University College London Hospitals, studied 22 patients who developed the syndrome after receiving AstraZeneca's vaccine, and found they had an unusual antibody response. These so-called anti-PF4 antibodies had only been seen before as a rare reaction to the use of the common blood thinner heparin.


    The findings support a theory that an immune reaction might underlie the rare blood clots, but the findings don't yet explain it, Scully and colleagues reported in the New England Journal of Medicine Friday. What may be going on is a reaction by the immune system with platelets to cause uncontrolled clotting.


    If vaccines cause it, it's still very rare and unusual, they wrote. It might not even be happening any more often in recently vaccinated people than among the population in general.


    "The risk of thrombocytopenia and the risk of venous thromboembolism after vaccination against SARS-CoV-2 do not appear to be higher than the background risks in the general population, a finding consistent with the rare and sporadic nature of this syndrome," they wrote.

    The events reported in this study appear to be rare, and until further analysis is performed, it is difficult to predict who may be affected. The symptoms developed more than five days after the first vaccine dose," they added.


    "In all cases reported to date, this syndrome of thrombocytopenia (low platelet count) and venous thrombosis (blood clot) appears to be triggered by receipt of the first dose of the (AstraZeneca) ChAdOx1 nCoV-19 vaccine. Although there have been a few reports of patients with symptoms consistent with this clinical syndrome after the receipt of other vaccines against SARS-CoV-2, none have yet been confirmed to fulfill the diagnostic criteria," they added.


    But if vaccination can cause the condition, it would be important to recognize that and treat it appropriately -- because the usual treatment for blood clots is not recommended for VITT.

    New Side Effect From mRNA COVID Vaccines?

    — Surprise finding in Israeli case series


    https://www.medpagetoday.com/i…ease/covid19vaccine/92106


    Little has been known about the safety and efficacy of the COVID-19 vaccines among patients with rheumatic diseases, because immunosuppressed individuals were not included in the initial clinical trials, they explained.


    Accordingly, an observational study has been conducted at the Tel Aviv Medical Center and the Carmel Medical Center in Haifa, monitoring post-vaccination adverse events in patients with rheumatoid arthritis, spondyloarthropathies, connective tissue diseases, vasculitis, and myositis. This interim analysis included 491 patients and 99 controls, with events reported during the 6-week post-vaccination monitoring period. The prevalence among patients was 1.2% versus none in controls, Furer and colleagues reported in Rheumatology.


    "We haven't seen any additional cases so far," Furer told MedPage Today. However, "further surveillance of potential adverse effects following anti-COVID-19 vaccination in patients with rheumatic diseases is warranted," she added.


    The Cases


    Case 1 was a 44-year-old woman with Sjogren's syndrome who was being treated with hydroxychloroquine. She had a history of varicella and had not received a shingles vaccine. Three days after the first dose of the vaccine, she developed a vesicular skin rash with pruritus, along with low back pain and headache. The symptoms resolved spontaneously within the subsequent 3 weeks without treatment, and she was given the second dose 4 weeks after the first.

    Case 2 was a 56-year-old woman with a long history of seropositive rheumatoid arthritis who had received a variety of biologics and had achieved low disease activity with tofacitinib (Xeljanz) beginning in 2014. She had a history of varicella and had not been given the shingles vaccine.


    After the first dose of the vaccine, she reported malaise and headache, and 4 days after the shot she developed severe pain in the left eye and forehead, along with a rash along the distribution of the ophthalmic division of the V cranial nerve -- herpes zoster ophthalmicus. Ocular examination revealed hyperemic conjunctivitis sparing the cornea. She was given a 2-week course of acyclovir and analgesics, and symptoms gradually cleared by 6 weeks. Tofacitinib was withdrawn for 2 weeks, but she did not experience an arthritis flare. She declined the second dose.


    Case 3 was a 59-year-old woman with seropositive rheumatoid arthritis who had not responded to several biologic therapies and baricitinib (Olumiant), but 6 months earlier she initiated treatment with upadacitinib (Rinvoq) plus prednisone 5 mg/day and had a partial response. She had a history of varicella and had been given the live attenuated zoster vaccine in 2019.



    Two days after receiving the second dose of the COVID vaccine, she reported pain and had a vesicular skin rash on the lower abdomen, inguinal area, buttock, and thigh, and was given valacyclovir. The antiviral was given for 3 days but was discontinued because of adverse effects, and the skin lesions healed slowly over a course of 6 weeks.


    The upadacitinib had been discontinued with the zoster eruption and she experienced a severe rheumatoid arthritis disease flare affecting multiple joints, and her arthritis treatment was subsequently switched to etanercept (Enbrel).


    Case 4 was a 36-year-old woman with a long history of seropositive rheumatoid arthritis plus interstitial lung disease. For the previous 2 years she had been treated with rituximab (Rituxan), mycophenolate mofetil (CellCept), and prednisone in doses of 7 mg/day. She had a history of varicella and had not been given the shingles vaccine.


    Ten days after receiving the first COVID-19 vaccine dose, she reported pain and a vesicular rash on the abdomen and back along the T10 dermatome, and was given acyclovir for 7 days. The rash resolved within 6 weeks, and she was given the second vaccine dose 4 weeks after the first. She had no further adverse effects to the vaccine and did not experience a rheumatic disease flare.

    Case 5 was a 38-year-old woman with undifferentiated connective tissue disease and antiphospholipid syndrome who was being treated with aspirin and hydroxychloroquine. She had prior varicella exposure and had not received the shingles vaccine.


    Two weeks after receiving the first dose of the COVID-19 vaccine, she developed an itchy vesicular rash on the right breast, and was given a week's course of acyclovir. Her zoster symptoms resolved within 3 weeks and she received the second vaccine dose on schedule with no further side effects or disease flare.


    Case 6 was a 61-year-old woman with a long history of seropositive rheumatoid arthritis, who was being treated with tocilizumab (Actemra) and prednisone 5 mg/day at the time of the first dose of the vaccine. Two weeks later, a rash appeared along the T6 dermatome, and she was given valacyclovir for a week, which resulted in resolution of zoster symptoms within 10 days.

    However, she did report a mild flare of arthritis and the prednisone dose was increased to 7.5 mg/day. The second dose was given uneventfully as scheduled.


    Patterns and Mechanisms


    Furer and colleagues noted that there had been no reports of herpes zoster in the clinical trials of the mRNA COVID-19 vaccines, and that, to their knowledge, this is the first case series of these events among patients with autoimmune/inflammatory diseases.


    The pattern of disease was relatively mild, with no patients experiencing disseminated disease or post-herpetic neuralgia. It was notable, the researchers pointed out, that one case was in a patient who had received the shingles vaccine 2 years before the COVID-19 vaccination.


    "Cell-mediated immunity plays an important role in the prevention of varicella zoster virus reactivation. Declining cell-mediated immunity with age or disease is associated with a reduction in varicella zoster virus-specific T cells, disrupting immune surveillance and increasing the risk of reactivation, with age being the major risk factor for 90% of cases of herpes zoster," the researchers wrote. Nonetheless, these cases were among relatively young women, whose mean age was 49 and whose rheumatic disease was mild or stable.

    Other factors are also likely to have been involved. For instance, the risk of herpes zoster in the rheumatic disease population is higher than healthy individuals, with a pooled incidence rate ratio of 2.9 (95% CI 2.4-3.3). In addition, the risk among patients with rheumatoid arthritis specifically has been estimated to be twofold higher than in the general population.


    Further raising risk are increased levels of disease activity and high doses of prednisone. Moreover, double the risk of herpes zoster has been reported for patients being treated with JAK inhibitors such as tofacitinib, as was the case with two patients in this series.


    COVID-19 infection itself has been linked with varicella-like rashes, suggesting that the infection can interfere with the activation and function of CD4+ and CD8+ cells, which can influence immunity against viruses.


    "Potential mechanisms that might explain the pathogenetic link between mRNA-COVID-19 vaccination and herpes zoster reactivation are related to stimulation of innate immunity through toll-like receptors," the researchers wrote.


    They also noted that the vaccine can stimulate type I interferons and cytokines that can interfere with antigen expression.


    A limitation of this analysis was that the diagnosis of herpes zoster was made solely on clinical grounds. Also, with only a small number of cases, causality cannot be assumed.

    How much money will Pfizer and Moderna make from their booster shots?


    https://qz.com/1997697/will-pf…ovid-19-booster-shot/amp/


    The Pfizer vaccine will need a booster shot, likely within a year of completing the first two doses, the company’s CEO, Albert Bourla, said in comments taped April 1, and released yesterday by Pfizer.


    Moderna, too, announced a plan to have a booster shot ready its two-dose vaccine course ready by the fall.


    This was always a possible scenario for the immunization campaign. Data on the duration of immunity so far shows both Pfizer and Moderna’s vaccines—both made using mRNA technology—are highly effective six months after the shots, but the boosters would extend strong immunity further, and potentially protect against emerging variants.


    More shots, more money for Pfizer and Moderna

    Vaccines don’t come for free, though, and providing a booster shot for current regimens is likely to be the first indicator of how much drug companies can earn from their Covid-19 vaccines in the long term.

    Pfizer and Moderna didn’t respond to Quartz’s request for details on prospective booster shot pricing, but it’s possible to estimate revenues for them based on a few considerations.


    “Sold at present prices, this would represent roughly a 50% increase in revenue over the longer run,” says Christopher Snyder, an economics professor at Dartmouth who has been studying the economic aspects of vaccine development.


    Moderna’s forecast for sales of the first two doses of the vaccine was $18.4 billion for 2021, so the booster shot could add about $9 billion to that. Pfizer projected at least $15 billion in sales for 1 billion Covid-19 vaccine doses, so the booster would bring an additional $7.5 billion to the pharma giant.

    We are all in this together????


    J&J reportedly sought help from rivals after blood clot concerns emerged


    https://amp.cnn.com/cnn/2021/0…pfizer-moderna/index.html


    York(CNN)Johnson & Johnson sought help from its three rival Covid-19 vaccine makers to look into reports of blood clots, but Pfizer and Moderna both declined, the Wall Street Journal reported on Friday, citing people familiar with the situation. Only AstraZeneca agreed, according to the WSJ.


    J&J also wanted to build an informal alliance with its competitors that it hoped would allow the industry to speak with one voice about the safety of the vaccines and address any public concerns about the blood-clot cases, the Journal reported.


    In a statement to CNN on Friday, a Pfizer (PFE) spokesperson declined to comment on the specifics of the WSJ report. "Pfizer embraces opportunities for scientific exchange when we can make a meaningful contribution that is not being represented by other groups or regulators," the spokesperson said. "We have and will continue to collaborate with other vaccine makers as appropriate as we all fight against this deadly pandemic."

    Reference?

    He read the headline but not the story or excemptions


    Doctors’ Newfound Immunity to Medical Malpractice Lawsuits During COVID-19 Pandemic


    https://attorneyatlawmagazine.…-during-covid-19-pandemic


    The COVID-19 pandemic has created a healthcare crisis around the world. As governments continue to grapple with the pandemic’s immediate impact, the medical sector’s working conditions have experienced drastic changes. Healthcare facilities are overcrowded, critical equipment is scarce, and care providers are overworked.


    For that reason, emergency declarations have been issued in all 50 states in the United States. Some of these protections pertain to acts of “good faith” healthcare, which means that a healthcare provider would receive additional graces or extended liberties.

    However, these measures don’t cover reckless misconduct, intentional infliction of harm, willful criminal misconduct, or gross negligence. These changes also seek to address issues of COVID-19 patients and victims of healthcare malpractice.


    If you or someone you love has been a victim of medical malpractice, you can consult reputable legal professionals like this to receive the justice you deserve.